CD8A and neoplasm: Consistent with in vitro findings, in vivo studies revealed that TS-PP@FU, in combination with anti-programmed death-1, markedly inhibited tumor progression, reversed the immunosuppressive TME landscape, and facilitated robust CD8+ T-cell infiltration, successfully transforming “cold tumors” into anti-programmed death-1-responsive “hot tumors”.